key: cord-0934852-twhnrse7 authors: von Tresckow, Julia; von Tresckow, Bastian; Reinhardt, H. Christian; Herrman, Ken; Berliner, Christoph title: Thymic Hyperplasia after mRNA based Covid-19 Vaccination date: 2021-08-26 journal: Radiol Case Rep DOI: 10.1016/j.radcr.2021.08.050 sha: 22713f79e5e64fd93fdda2bc66371febefb1741b doc_id: 934852 cord_uid: twhnrse7 Reactive lymphadenopathy with increased 18F-Fluordeoxyglucose (FDG) uptake in positron emission tomography (PET)/computed tomography (CT) scans is known after mRNA vaccination (BNT162B2, mRNA-1273) against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV2). Besides this, increased FDG uptake in the thymus might occur after mRNA vaccination as shown in our case of a young patient with mantle cell lmyphoma. Especially in patients with lymphoma but also in other patients with cancer it is critical to distinguish between immune responses and involvement of the disease to avoid inadequate treatment decisions. Reactive lymphadenopathy with increased 18F-Fluordeoxyglucose (FDG) uptake in positron emission tomography (PET)/computed tomography (CT) scans occurs in up to 16% of patients after mRNA vaccination (BNT162B2, mRNA-1273) against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV2). It has not yet been described for the adenoviral vector vaccine JNJ-78436735 1,2 and only sporadically for AZD1222 3 . Lymphadenopathy due to vaccination might confound initial disease assessment and restaging thereby hampering optimal therapy in patients with cancer. It is known that, SARS-CoV-2 infection might lead to thymic hyperplasia 4 in addition to lymphadenopathy. However, thymic hyperplasia has thus far not been described after SARS-CoV2 vaccination. Case report Here, we report the case of a 35-year-old female patient who was admitted to our hospital with first diagnosed mantle cell lymphoma (MCL). No concomitant diseases were known. Patient reported no disease-related complaints and particularly no B symptoms. Physical examination as well as testing of laboratory values showed no pathological findings. The diagnosis was made by resection of a coincidentally detected enlarged right cervical lymph node. Histopathologic findings showed partial infiltration with mantle zone proliferation and confluence. A Ki67 of <10%, expression of cyclin D1 and SOX11, and clonality of IgH were noted. Bone marrow biopsy excluded infiltration. Shortly after diagnosis, the patient was vaccinated with mRNA-1273 in the left upper arm. The vaccination was well tolerated. On day +36 after vaccination, the patient showed a strong SARS-CoV-2 IgG antibody response (ELISA Euroimmun with ratio 8.80, positive over 1.1 ratio of patient sample/control sample) and weakly measurable T-cell immunity in Oxford Immunotec EliSpot from 5 spikes (T-SPOT.COVID positive over 6 specific spikes). 10 days after vaccination, an 18F-FDG PET/CT staging displayed moderately increased uptake in the cervical right region, but markedly increased uptake in the axillary left and anterior superior mediastinal regions ( Figure 1 ). Clinically, the axillary lymphadenopathy disappeared a few days after immunization. Since radiotherapy with curative intent was planned and thymic involvement of MCL would have made localized radiotherapy unfeasible, a diagnostic thymus resection was performed 5 . Histology showed hyperplasia of the thymus without infiltration of the lymphoma (Figure 1 ), possibly as an immunologic response to vaccination. Therefore, the patient is referred to local radiotherapy of the affected cervical lymph node region with curative intent. Our case brought out that markedly increased uptake in 18F-FDG PET/CT scans with temporal association to vaccination with mRNA-based vaccines may occur not only in regional lymph nodes but also in the thymus. In the context of cancer, it is critical to distinguish such immune responses from involvement by malignancy to avoid false positive staging results that may lead to inadequate treatment decisions. Written informed consent for publication was obtained from the patient. JvT -support for the present manuscript: none; Grants or contracts: Janssen-Cilag, Roche; Royalties or licenses: none; Consulting fees: AbbVie, Janssen, Roche; Payment or honoraria: AbbVie, AstraZeneca, Janssen, Roche; Payment for expert testimony: none; Support for attending meetings and/or travel: AbbVie, AstraZeneca, Celgene, Janssen, Roche; Patents planned: none; Leadership or fiduciary role in other board, society, committee or advocacy group: none; Stock or stock options: none. Axillary Lymph Nodes Hypermetabolism After BNT162b2 mRNA COVID-19 Vaccination in Cancer Patients Undergoing 18F-FDG PET/CT: A Cohort Study The Effect of COVID-19 Vaccination on FDG PET/CT Lymphadenopathy Following COVID-19 Vaccination: Imaging Findings Review Protective reactive thymus hyperplasia in COVID-19 acute respiratory distress syndrome Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup BvT -support for the present manuscript: none; Grants or contracts: MSD, Takeda, Novartis; Royalties or licenses: none; Consulting fees: BMS, Amgen, Pfizer, Gilead, Roche, MSD, Takeda, Novartis; Payment or honoraria: BMS, Amgen, Pfizer, Gilead, Roche, MSD, Takeda, Novartis; Payment for expert testimony: none; Support for attending meetings and/or travel: BMS, MSD, Takeda, Novartis; Patents planned: none; Leadership or fiduciary role in other board, society, committee or advocacy group: none; Stock or stock options: none.HCR -support for the present manuscript: none; Grants or contracts: none; Royalties or licenses: none; Consulting fees: none; Payment or honoraria: none; Payment for expert testimony: none; Support for attending meetings and/or travel: none; Patents planned: none; Leadership or fiduciary role in other board, society, committee or advocacy group: none; Stock or stock options: none.KH -support for the present manuscript: none; Grants or contracts: BTG; Royalties or licenses: none; Consulting fees: ABX, Aktis Oncology, Bayer, Novartis, ymabs; Payment or honoraria: Adacap, Amgen, Bayer, BTG, Curium, Endocyte, GE Healthcare, IPSEN, Pharma15 , Sofie Biosciences, Siemens Healthineers, SIRTEX, Theragnostics; Payment for expert testimony: none; Support for attending meetings and/or travel: none; Patents planned: none; Leadership or fiduciary role in other board, society, committee or advocacy group: none; Stock or stock options: none.CB -support for the present manuscript: none; Grants or contracts: none; Royalties or licenses: none; Consulting fees: none; Payment or honoraria: Janssen; Payment for expert testimony: none; Support for attending meetings and/or travel: none; Patents planned: none; Leadership or fiduciary role in other board, society, committee or advocacy group: none; Stock or stock options: none.